Pfizer, Novartis and more post price hikes on dozens of drugs, but AbbVie’s is worth the most

It's not just specialty drugmakers raising prices in recent days. Big Pharma has pushed through a spate of increases, and while all of them are sub-10% the cap some companies have adopted—some of them will cost payers and consumers plenty. A single price increase, in fact, could add more than $1 billion to the U.S. healthcare system's drug bill this year, one analyst figures: AbbVie's 9.7% hike on its megablockbuster Humira. Wells Fargo's David Maris and his team dug into Medi-Span Price Rx data for the period from Dec. 15 to Jan. 3 and found the stickers for dozens of pharma's big-selling drugs grew during that time. None of the companies they investigated implemented a price hike higher than 9.9%, Maris wrote in a note on Thursday.